Patent US4069343A successfully refreshed from Google Patents.
US4069343A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Oxamic acid derivatives for the prevention of immediate type hypersensitivity reactions
Assignee: Wyeth LLC
•
Filing: 1976-03-23
•
Granted: 1978-01-17
•
Expires: 1996-03-23
Abstract
Abstract Anti-allergic agents of aromatic oxamic acid derivation present the following formula: ##STR1## in which A is a member selected from the group consisting of α-naphthyl, β-naphthyl, phenyl, 2,6-dichlorophenyl, and substituted phenyl moieties containing from one to three substituents in any of the 2,3,4 and 5 positions of the phenyl ring, independently selected from the group consisting of lower alkyl, lower alkylthio, lower alkylsulfinyl, lower alkoxy, hydroxy (lower)alkoxy, 2-(oxalyloxy) ethoxy, benzyloxy, N-mono- and di-lower alkylamino(lower)alkoxy, halo, sulfamyl, polyhalo(lower)alkyl, carbamyl, N-lower alkylcarbamyl, nitro, mono and di lower alkylamino, carboxy, lower alkylcarbonyl, carb(lower)alkoxy, phenoxy(lower)alkoxy, and oxalamidophenoxy radicals; And pharmaceutically acceptable salts thereof.
Inventors
- 👤 John H. Sellstedt
- 👤 Charles J. Guinosso
- 👤 Albert J. Begany
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-07 08:23
CPC Classifications
C; C07; C07D; C07D257/00; C07D257/02; C07D257/04; C07C; C07C245/00; C07C245/02; C07C245/06; C07C245/08
Claims Analysis
Total Claims: 15
Claim 1
Independent Claim
147 words
A process for preventing the release of pharmacological mediators from an immediate hypersensitivity reaction between reaginic type antibodies and an antigen, thereby preventing the symptoms manifest in bronchial asthma, seasonal pollinosis, allergic rhinitis, urticaria, allergic conjunctivities, food allergy and anaphylactoid reactions of a sensitized animal, which comprises prophylactically administering to said animal an effective amount of a compound of the formula: ##STR6## in which A is a member selected from the group consisting of α-naphthyl, β-naphthyl, phenyl, 2,6-dichlorophenyl and substituted phenyl moieties containing from one to three substituents in any of the 2,3,4and 5 positions of the phenyl ring, independently selected from the group consisting of lower alkyl, lower alkylthio, lower akylsulfinyl lower alkoxy, hydroxy(lower)alkoxy, 2-(oxalyloxy)ethoxy, benzyloxy, N-mono- and di- lower alkylamino-(lower)-alkoxy, halo, sulfamyl, polyhalo(lower)alkyl, carbamyl, N-lower alkylcarbamyl, nitro, mono- and di-lower alkylamino, carboxy, lower alkylcarbonyl, carb(lower)alkoxy, phenoxy(lower)alkoxy, and oxalamidophenoxy radicals; or a pharmaceutically acceptable salt thereof.
Claim 2
Dependent Claim
147 words
A process for preventing the release of pharmacological mediators from an immediate hypersensitivity reaction between reaginic type antibodies and an antigen, thereby preventing the symptoms manifest in bronchial asthma, seasonal pollinosis, allergic rhinitis, urticaria, allergic conjunctivities, food allergy and anaphylactoid reactions of a sensitized animal, which comprises prophylactically administering to said animal an effective amount of a compound of the formula: ##STR6## in which A is a member selected from the group consisting of α-naphthyl, β-naphthyl, phenyl, 2,6-dichlorophenyl and substituted phenyl moieties containing from one to three substituents in any of the 2,3,4and 5 positions of the phenyl ring, independently selected from the group consisting of lower alkyl, lower alkylthio, lower akylsulfinyl lower alkoxy, hydroxy(lower)alkoxy, 2-(oxalyloxy)ethoxy, benzyloxy, N-mono- and di- lower alkylamino-(lower)-alkoxy, halo, sulfamyl, polyhalo(lower)alkyl, carbamyl, N-lower alkylcarbamyl, nitro, mono- and di-lower alkylamino, carboxy, lower alkylcarbonyl, carb(lower)alkoxy, phenoxy(lower)alkoxy, and oxalamidophenoxy radicals; or a pharmaceutically acceptable salt thereof.
Claim 3
Dependent Claim
91 words
The process of claim 1 which comprises administering to said sensitive animal a compound of the formula: ##STR7## in which A is a member selected from the group consisting of α-naphthyl, β-naphthyl, phenyl, 2,6-dichlorophenyl and substituted phenyl moieties containing from one to three substituents, in any of the 2,3,4 and 5 positions of the phenyl ring, independently selected from the group consisting of lower alkyl, fluoro, lower alkoxy, hydroxy(lower) alkoxy, (lower)alkylthio, N-mono or di-(lower) alkylamino(lower)alkoxy, carbamoyl, carb(lower)-alkoxy, trifluoromethyl, nitro, phenoxy(lower)alkoxy radicals and 2-(oxalyloxy) ethoxy radicals; or a pharmaceutically acceptable salt thereof.
Claim 4
Dependent Claim
18 words
The process of claim 1 in which said compound is 2'-carbamoyl-3'-methoxyoxanilic acid or a pharmaceutically acceptable salt thereof.
Claim 5
Dependent Claim
18 words
The process of claim 1 in which said compound is 2'-carbamoyl-3'-(2-phenoxyethoxy)oxanilic acid or a pharmaceutically acceptable salt thereof.
Claim 6
Dependent Claim
18 words
The process of claim 1 in which said compound is 2'-carbamoyl-3'-ethoxyoxanilic acid or a pharmaceutically acceptable salt thereof.
Claim 7
Dependent Claim
18 words
The process of claim 1 in which said compound is 2'-carbamoyl-3'-propoxyoxanilic acid or a pharmaceutically acceptable salt thereof.
Claim 8
Dependent Claim
18 words
The process of claim 1 in which said compound is 2'-carbamoyl-3'-isopropoxyoxanilic acid or a pharmaceutically acceptable salt thereof.
Claim 9
Dependent Claim
18 words
The process of claim 1 in which said compound is 2'-carbamoyl-3'-n-butoxyoxanilic acid or a pharmaceutically acceptable salt thereof.
Claim 10
Dependent Claim
18 words
The process of claim 1 in which said compound is 2'-carbamoyl-3'-(2-dimethylaminoethoxy)oxanilic acid or a pharmaceutically acceptable salt thereof.
Claim 11
Dependent Claim
18 words
The process of claim 1 in which said compound is 2'-carbamoyl-3'-(2-hydroxypropoxy)oxanilic acid or a pharmaceutically acceptable salt thereof.
Claim 12
Dependent Claim
18 words
The process of claim 1 in which said compound is (2-carbamoyl-3,5-dimethoxyphenyl)oxamic acid or a pharmaceutically acceptable salt thereof.
Claim 13
Dependent Claim
18 words
The process of claim 1 in which said compound is [2-carbamoyl-3-(2-hydroxyethoxy)phenyl]oxamic acid or a pharmaceutically acceptable salt thereof.
Claim 14
Dependent Claim
18 words
The process of claim 1 in which said compound is [2-(aminocarbonyl)-3-(dimethylamino)phenyl]oxamic acid or a pharmaceutically acceptable salt thereof.
Claim 15
Dependent Claim
18 words
The process of claim 1 in which said compound is [2-carbamoyl-3-(methylthio)phenyl]oxamic acid or a pharmaceutically acceptable salt thereof.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1981-01-16 | 1981-07-18 | 1982-01-17 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1985-01-16 | 1985-07-18 | 1986-01-17 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1989-01-16 | 1989-07-18 | 1990-01-17 | $7700.00 | Window Closed / Lapsed |